TY  - JOUR
TI  - Eltrombopag for Treatment of Thrombocytopenia Following
Hematopoietic Stem Cell Transplantation
AB  - Objective: This study aimed to evaluate the efficacy and safety of
eltrombopag (ELT) in the treatment of thrombocytopenia following
hematopoietic stem cell transplantation (HSCT).
Materials and Methods: Forty-eight patients treated with ELT for
thrombocytopenia after allogeneic or autologous transplantation at
the Erciyes University Bone Marrow Transplantation Center between
July 2017 and July 2021 were evaluated retrospectively.
Results: Forty-eight HSCT recipients were included in this study.
Thirty (62.5%) patients were evaluated as having experienced delayed
platelet recovery (DPR) and 18 (37.5%) patients as having experienced
secondary failure of platelet recovery (SFPR). The median platelet
count before ELT treatment was 13x109
/L (range: 3-20x109
/L). Twentythree patients responded to treatment and the cumulative incidence
of successful platelet recovery was 48%. Patients with both DPR
and SFPR responded, but patients with DPR had a higher response
rate (50% vs. 44%). The median platelet count of the 23 responding
patients was 12x109
/L (5-19x109
/L) before treatment and 68x109
/L
(52-266x109
/L) after treatment (p<0.0001). While the number of bone
marrow megakaryocytes before treatment was adequate in 22 (46%)
cases, it was decreased in 26 (54%) cases. Patients with adequate bone
marrow megakaryocytes had a better response rate than those without
(77% vs. 23%, p<0.0001). The group with adequate megakaryocytes
responded to treatment at a median of 33 days (range: 9-174 days).
Patients with decreased megakaryocytes responded at a median of
55 days (30-164 days) (p=0.002). No drug-related side effects were
observed in any patients.
Conclusion: This real-life experience demonstrates that ELT is an
effective and safe treatment option for thrombocytopenia after HSCT.
The adequacy of bone marrow megakaryocytes before ELT treatment
was an important factor affecting response to treatment.
AU  - Kaynar, Leylagul
AU  - ÇETİN, Mustafa
AU  - ÜNAL, Ali
AU  - Guven, Zeynep Tugba
AU  - ÇELİK, Serhat
AU  - Eser, Bülent
DO  - 10.4274/tjh.galenos.2022.2021.0675
PY  - 2022
JO  - Turkish Journal of Hematology
VL  - 39
IS  - 2
SN  - 1300-7777
SP  - 103
EP  - 108
DB  - TRDizin
UR  - http://search/yayin/detay/515138
ER  -